Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

Results from phase II trial with thalidomide for prostate cancer reported

June 18, 1997

Suntory prepares compounds for thrombocytopenia

June 17, 1997

Merck & Co. prepares improved inhibitors of protein farnesyltransferase

June 17, 1997

U.S. notice of patent allowance for troponin I

June 16, 1997

Banyu to shift development from NB-506 to new indolocarbazole

June 13, 1997

Paracelsian cancels launch of AndroCar

June 12, 1997

Milkhaus initiates phase II trial for prostate cancer

June 11, 1997

FDA Oncologic Drugs Advisory Committee to review three NDAs in late June

June 11, 1997

Vical's Leuvectin enters phase I/II for prostate cancer

June 11, 1997

Synthelabo and Praecis collaborate on prostate cancer product

June 10, 1997

Popular Stories

Today's news in brief
BioWorld
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...
VST Bio’s VB-001 is neuroprotector after stroke
BioWorld Science
At the recent International Stroke Conference, researchers from VST Bio Corp. and Yale University presented preclinical data regarding VB-001, a monoclonal...